|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the PSA levels were correlated with the expression of DRD1 in BPH cases and DRD1, DRD4, DRD5, and IL6 in PCa cases.
|
31288722 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We first profiled global serum miRNAs in a pilot set of PCa and benign prostatic hyperplasia (BPH) cases undergoing TRUS-guided prostate biopsy due to elevated PSA levels.
|
31534967 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we described an Italian pedigree affected by HHL but also prostate hyperplasia and increased ratio of the free/total PSA levels, with the unusual and extremely rare Y-linked pattern of inheritance.
|
30341416 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study.
|
31569672 |
2019 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PSA level was significantly higher in the PCa group than in BPH (18.2 versus 9 ng/mL, <i>p</i> < 0.01), while volume of prostate gland was significantly higher in the BPH group than in PCa (39.1 versus 31.1 cm<sup>3</sup>, <i>p</i> = 0.02).
|
30186533 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnostic efficiency of exosomal ephrinA2 was superior to that of whole serum ephrinA2 and serum PSA in distinguishing PCa patients from those from BPH patents.
|
30087706 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with PSA ≤20 ng/ml, T/PSA was higher in those with BPH than in those with PCa (4.69 versus 2.24; p < .001).
|
28752596 |
2018 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the combination of MIC-1 and PSA was allowing 99.1% AUC for the differentiation of BPH + PC from HC, 97.9% AUC for differentiation of BPH from HC, 98.6% AUC for differentiation of PC from HC, and 96.7% AUC for the differentiation of PC from BPH.
|
29203798 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Insulin was increased and IGFBP-3/PSA was reduced in BPH patients with increased prostate size.
|
28300542 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia.
|
29100363 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Histology of prostate revealed hyperplasia of transition lobe, increased expression of PSA, and Ki67 in BPH.
|
28211173 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PSA-158G/A polymorphism may be an inhibitor to the incidence of BPH in Caucasians, but it is likely to be a susceptible factor in Asians.
|
28430620 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the more sensitive nanoparticle-based lectin-immunoassay we detected a statistically significant increase in the PSA fucosylation in PCa tissue compared to benign tissue (p=0.001) and in urine from PCa patients compared to BPH patients (p=0.030), and an even greater discrimination (p=0.010) when comparing BPH patients to PCa patients with Gleason score≥7.
|
27818346 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA showed high immunoexpression in all BPH patients and a focal positivity in Ser-Se-Ly treated patients after 3 months.
|
28327526 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Receiver-operating characteristic curve (ROC) revealed that miR-145 in UEVs combined with serum PSA could differentiate PCa from BPH better than PSA alone (AUC 0.863 and AUC 0.805, respectively).
|
28617988 |
2017 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
|
26831660 |
2016 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunostaining, ELISA, and in situ hybridization analyses of BPH tissues verified the presence of PSA protein but absence of PSA mRNA in the stromal compartment.
|
24711254 |
2014 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Receiver Operating Curve (ROC) analysis demonstrated that TSP2 transcript levels can better distinguish PCa from BPH tissue samples (P<0.01) than serum PSA levels (P=0.299).
|
23470460 |
2013 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, effects of the 14 SNPs on BPH related clinical traits, including International Prostate Symptom Score (IPSS), prostate volume, total PSA, and free PSA were evaluated using linear regression analysis.
|
23620269 |
2013 |
|
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using quantitative real-time polymerase chain reaction, we found a significant upregulation of AR and PSA mRNA expression in CaP comparison to BPH.
|
22731640 |
2012 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggested that circulating miRNAs could serve as biomarkers for CaP, and compared to single miRNA, the 5 miRNAs panel can accurately discriminate CaP from BPH and healthy controls with high sensitivity and specificity, and therefore, combined with routine PSA test, these 5 CaP-specific miRNAs may help improve CaP diagnosis in clinical application.
|
22298030 |
2012 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was to determine whether PSCA mRNA positivity in preoperatively negative prostatic biopsy samples from BPH men with PSA > 4.0 ng/ml and/or suspicious DRE findings had predictive performance following TURP.
|
19462463 |
2009 |
|
Benign Prostatic Hyperplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A novel splice variant of PSA was identified, PSA-SV5, that may be exploited in clinical diagnosis to distinguish prostate cancer from benign prostate hyperplasia.
|
18222179 |
2008 |
|
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study suggests that the detection of GSTP1 methylation in prediagnostic urine may improve the specificity of PSA and help distinguish men with prostate cancer from those with benign prostatic hyperplasia.
|
18076912 |
2008 |